Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Avatar Builder  |  Contact Info  |  Update Email  |  Update Password  |  Leaderboards  |  Manage Favourite  |  Reputation  |  Reputation History  |  Subscriptions  |  Payment Info  |  Invoices  |  Favourites

Bullboard Post History

by Breakthorough1

IMVIQ

RE:Anyone know when we are going to actually get clinical news?

If we are to follow the poster at the conference today: - ASCO (Ovarian...

February 11, 2019

IMVIQ

RE:RE:RE:RE:Clinical Update for DPX-Survivac Program in Ovarian Cancer

Well, GoergeousGeorge1, I guess we are all asking ourselves the same thing......

January 29, 2019

IMVIQ

RE:Clinical Update for DPX-Survivac Program in Ovarian Cancer

Looks good: "The FDA reviewed the Company's proposed clinical...

January 29, 2019

IMVIQ

The future?

First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes...

January 17, 2019

IMVIQ

RE:RE:RE:Meeting

In this link you can find the guidelines related to Pre-Submissions and...

December 31, 2018

IMVIQ

RE:RE:RE:RE:Positive Date From Phase 1b/2

Ops: in 2019 they are going to move the technology to other targets apart...

December 13, 2018

IMVIQ

RE:RE:Positive Date From Phase 1b/2

Much less clinical benefit in the higher dose of Epacadostat (even if the...

December 13, 2018

IMVIQ

HERE THEY ARE! And are very good.

On a total evaluable population of 32 patients: 12 with PR (>30...

December 13, 2018

IMVIQ

RE:RE:RE:RE:RE:RE:RE:Updated Clinical Data Presentation

Hi, PoorOpinion: In the abstract they literally say: "Four partial...

December 11, 2018

IMVIQ

RE:RE:RE:RE:RE:Updated Clinical Data Presentation

I guess I am wrong. They don't say 9 SD, but 9 DCR. So the DCR in the...

December 10, 2018

IMVIQ

RE:RE:RE:RE:Updated Clinical Data Presentation

PoorOpinion, I guess your interpretation of the data is right, but it reamins...

December 10, 2018

IMVIQ

RE:Don't even have to read between the lines anymore...

Literally: "We believe that it's reasonable for us to expect that...

November 27, 2018

IMVIQ

RE:RE:RE:RE:RE:NCIC Trials

Just found that In september the 6th pressentation the DPXE7 trial topline...

November 26, 2018

IMVIQ

RE:RE:RE:NCIC Trials

And what about the DPX-E7 (HPV related cancers) one? It was supposed to give...

November 26, 2018

IMVIQ

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

Sorry, the format didn't fit. Imbruvica (first treatment approved...

November 20, 2018

IMVIQ

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

Here was the path of Imbruvica, the first treatment approved through "...

November 20, 2018

IMVIQ

RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

What he says is that he was trying to make of THIS ongoing trial (actually 18...

November 20, 2018

IMVIQ

RE:RE:RE:RE:RE:RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

Yes, 100% durable tumor regressions. 60% partial responses.

November 20, 2018

IMVIQ

RE:RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

Sorry, I correct myself. In the slide 4 of today's presentation, the...

November 20, 2018

IMVIQ

RE:RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer

They will disclose it in the presentation of the 14th. of December. No need...

November 20, 2018

Prev 1 2 3 4 5 6 7 8 9 10 11 Next

Featured Company

Westhaven Gold Corp.

Westhaven Gold Corp. V.WHN

Westhaven Gold Corp. is a Canada-based gold-focused exploration company. The Company is advancing the high-grade discovery on ... view more »